• Purity

  >95%, by SDS-PAGE with silver staining

• Endotoxin Level

  <0.10 EU per 1 μg of the protein by the LAL method.  

• Activity

  Measured by its ability to inhibit the FGF basic-dependent proliferation of HUVEC human umbilical vein endothelial cells. Dubrac, A.     et al. (2010) Blood     116:4703. The ED    ₅₀ for this effect is 2-10 μg/mL.

• Source

  E. coli-derived Val30-Ser105

• Accession #

• N-terminal Sequence    
  Analysis

  Val30

• Predicted Molecular Mass

  8.3 kDa

• SDS-PAGE

  9 kDa, reducing conditions

Background: CXCL4/PF4

CXCL4, also called PF4 (platelet factor 4), is an 8 kDa member of the CXC chemokine family, sharing features with CXCL8/IL-8 and CXCL7/NAP-2 (1-3). Mature rat CXCL4 shares 87% amino acid sequence identity with mouse CXCL4, and 65-76% amino acid sequence identity with human, mouse, bovine, ovine and porcine CXCL4. The active protein is a tetramer of CXCL4 subunits that forms a ring of heparin-binding positive charges from sites at the C-terminal region of each monomer (3). Megakaryocytes synthesize CXCL4 and store it in platelet alpha -granules (2, 3). Secretion from activated platelets can produce micromolar levels in serum and over 100-fold higher within clots (2, 3). In contrast to other CXC chemokines, CXCL4 does not contain an ELR motif and lacks binding to nearly all chemokine receptors (2, 3). In most cases, it is likely that cell surface binding and signaling properties of CXCL4 are due to binding of glycosaminoglycans chains, particularly chondroitin sulfates (2). CXCL4 released from activated platelets binds and regulates thrombin/thrombomodulin complexes, regulates and enhances production of activated Protein C (APC), and limits the coagulation cascade (2-6). It binds and influences the enzymatic activity of coagulation factor Xa (7). It binds fibrin and affects clot structure (8). Therapeutic doses of the anticoagulant heparin neutralize CXCL4 procoagulant effects (9). The complex between heparin and CXCL4 can be immunogenic, and circulating CXCL4-heparin antibodies cause the pathological syndrome HITT (heparin-induced thrombocytopenia and thrombosis, also called HIT) (2). In addition, immunogenic complexes of CXCL4 with apolipoprotein H can contribute to antiphospholipid syndrome (APS) (10). CXCL4 can be antiproliferative and antiangiogenic, at least in part via interfering with FGF-2 and VEGF heparin binding and thus inhibiting their signaling (3, 11-13). However, it can also be proinflammatory and pro-atherogenic through multiple effects on monocytes, macrophages and endothelial cells (2, 3).

• References:

1. Poncz, M. et al. (1987) Blood 69:219.

2. Kowalska, M.A. et al. (2010) Thromb. Res. 125:292.

3. Slungaard, A. (2005) Int. J. Biochem. Cell Biol. 37:1162.

4. Slungaard, A. et al. (2003) Blood 102:146.

5. Kowalska, M.A. et al. (2007) Blood 110:1903.

6. Preston, R.J.S. et al. (2009) J. Biol. Chem. 284:5869.

7. Fiore, M.M. and I.J. Mackie (2009) Biochem. Biophys. Res. Commun. 379:1072.

8. Amelot, A.A. et al. (2007) J. Biol. Chem. 282:710.

9. Eslin, D.E. et al. (2004) Blood 104:3173.

10. Sikara, M.P. et al. (2010) Blood 115:713.

11. Perollet, C. et al. (1998) Blood 91:3289.

12. Gengrinovitch, S. et al. (1995) J. Biol. Chem. 270:15059.

13. Sulpice, E. et al. (2004) Eur. J. Biochem. 271:3310.

• Entrez Gene IDs:

  5196 (Human); 56744 (Mouse); 360918 (Rat)

• Alternate Names:

  chemokine (C-X-C motif) ligand 4; C-X-C motif chemokine 4; CXCL4; CXCL4iroplact; Iroplact; MGC138298; Oncostatin-A; PF4; PF-4; platelet factor 4; SCYB4oncostatin-A